Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

Piflufolastat F-18 (Pylarify™) Compounding and Supply

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract with the National Institutes of Health involves the compounding and supply of Piflufolastat F-18 injection, known as Pylarify, for prime contractors on clinical projects. The selected provider must possess authorized commercial nuclear pharmacy licensing to compound radioactive drugs within clean rooms and hot cells in strict accordance with FDA and NRC regulations. Key responsibilities include ensuring precise activity levels and calibration, performing radiation monitoring, and conducting wipe testing to maintain safety and quality standards. The contractor is required to deliver patient-ready unit doses on demand to the place of performance in Bethesda. This specialized medical supply effort falls under NAICS code 325412 and is managed by the Department of Health and Human Services.

General Info

NIH subcontract for compounding and supplying Pylarify injections to clinical projects in Bethesda.

Agency

Department Of Health And Human Services → National Institutes Of Health - CcView Agency

NAICS

325412 - Pharmaceutical Preparation ManufacturingView NAICS

Place of Performance

Bethesda, MD, 20814, USA

Set-Aside

NONE

Documents

This scope was carved out of NOI-27-000004.

The full solicitation package (2 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health - Cc
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health - Cc
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Supplies patient-ready unit doses of Piflufolastat F-18 injection (Pylarify™) for prime contractors on NIH clinical projects. Compounds radioactive drugs in clean rooms and hot cells per FDA and NRC regulations, ensuring correct activity levels and calibration. Performs wipe testing and radiation monitoring. Requires authorized commercial nuclear pharmacy licensing. Delivers patient-ready unit doses on demand.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Health And Human Services → National Institutes Of Health - Cc

Same awarding agency

NAICS: 325412
New
Federal
Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)
Solicitation # NOI-27-000004
The National Institutes of Health Clinical Center intends to award a sole-source contract to Progenics Pharmaceuticals Inc., a Lantheus company, for the procurement of Piflufolastat F-18 injection (Pylarify). This FDA-approved radiopharmaceutical is used for the scintigraphic localization of prostate-specific membrane antigen positive lesions in men with prostate cancer. Due to the rapid radiation decay and short half-lives of the drug, it must be compounded, calibrated, and delivered as patient-ready unit doses on demand to the NIH Clinical Center Nuclear Pharmacy Facility in Bethesda, Maryland. The procurement is justified under FAR 8.405-6(b) and 41 U.S.C. 1901(a)(1) because Progenics Pharmaceuticals is the sole authorized provider and intellectual property owner capable of meeting the highly specialized quality and regulatory requirements of the FDA and the U.S. Nuclear Regulatory Commission. The contract is structured as an Indefinite Delivery/Indefinite Quantity requirement for 150 to 230 injections and four unused dose fees. The period of performance consists of a base year from October 1, 2026, to September 30, 2027, with four subsequent option years extending through September 30, 2031. The award will be made using GSA Contract 36F79719D0170 and includes an economic price adjustment clause per FAR 52.216-2 for 2026 pricing. Performance is measured by the accuracy of delivered doses, the absence of contamination, and strict adherence to federal regulatory standards.
Pharmaceutical Preparation Manufacturing

POSTED

1 day ago

DEADLINE

in 6 days
View Details
NAICS: 513210
New
Federal
Cloverleaf Security Server maintenance and support - Bethesda Site (Notice of Intent to sole source)
Solicitation # NOI-26-008015
The National Institutes of Health Clinical Center, Department of Clinical Research Informatics, intends to negotiate a sole source contract with Infor LLC for maintenance and support of the Cloverleaf Security Server at the Bethesda, Maryland site. This mission critical system provides essential encryption for the HL7 interface engine, which serves as the primary link between the Clinical Research Information System and various ancillary systems, including laboratory and radiology information systems. Because the software is proprietary to Infor and critical for the safe delivery of patient care and the protection of personally identifiable information, the government has determined that Infor is the only responsible source capable of providing the necessary maintenance and source code revisions. The period of performance is scheduled from September 26, 2026, to September 25, 2027. The scope of work includes the provision of no-cost application updates, email notifications for updates, 24x7 remote telephone technical support, and access to a 24x7 web knowledge base. Additionally, the contractor must maintain an established escalation process for critical issues. All deliverables must be marked with the date, offeror name, and task order details, with final inspection and acceptance conducted by the Contracting Officer's Representative at the NIH facility in Bethesda.
Software Publishers

POSTED

2 days ago

DEADLINE

in 1 day
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS